Tenofovir (TDF)- or Abacavir (ABC)-selected Minority Subpopulations in Viremic Subjects Detected by Ultra-deep Sequencing

R. T. D’Aquila¹, E. Rouse², J. Horton², A. Kheshti¹,³, S. Raffanti¹,³, K. Oie², K. Pappa², L.L. Ross²

¹Vanderbilt University School of Medicine; ²GlaxoSmithKline; ³Comprehensive Care Center

ICAAC/IDSA
DC, Oct. 26, 2008
Disclosures

- Study funded by GlaxoSmithKline
- R. D’Aquila relationships
  - Boehringer Ingelheim, Bristol Myers Squibb, Gilead, GlaxoSmithKline, Merck, Monogram, Tibotec, Virco
- E. Rouse, J. Horton, K. Oie, K. Pappa, L.L. Ross are each employed by GlaxoSmithKline
Background

- RT point mutations can concurrently reduce NRTI susceptibility and restrict HIV replication \textit{in vitro}.
  - HIV quasi-species can harbor minority variants
- TDF and ABC are associated with selection of K65R and L74V.
- Using ultra-deep sequencing, we tested the hypothesis that minor sub-populations with these mutations are often currently missed by population GT during viremia.
Methods

- Plasma-derived HIV was obtained from 16 viremic subjects who had received ABC, TFV or ZDV/3TC (control) based ART.
- Clones encompassing RT amino acids 56-120 were analyzed by high-throughput sequencing at ≥1 timepoint (454 Life Sciences).
- The percentages above calculated error rates* are reported (to exclude mutations produced by in vitro errors; probability <0.001)

Study Population

- Inclusion criteria:
  - Specimens archived (Vanderbilt/CCC and GSK) during failure of regimens with TDF or ABC;
  - Response to therapy with undetectable viremia;
  - Subsequent loss of virologic control (HIV-1 RNA levels above the limit of detection);
  - Subjects could have received a protease inhibitor or non-nucleoside inhibitor as part of their antiretroviral regimen along with TFV or ABC.

- Exclusion criteria:
  - >2 regimen failures
Key Concept

454 Sequencing from individual DNA molecules

Library of single stranded DNA molecules

\[ \downarrow \]

One DNA molecule per bead

\[ \downarrow \]

Clonal amplification of that single molecule to \( \sim 10 \) million copies

\[ \downarrow \]

Independent sequencing of each bead

\[ \downarrow \]

One Bead = One Read = One DNA molecule
RESULTS

- A median of 39,508 clones were analyzed per timepoint.
  - 9/16 subjects were on first line ART at failure.

- HIV-RNA was $\geq 3.8 \log_{10}$ copies/mL for all timepoints analyzed
## Clonal Analysis for Subjects Receiving a TDF-Based Regimen

<table>
<thead>
<tr>
<th>Subj. ID</th>
<th>A62V</th>
<th>K65R</th>
<th>D67G</th>
<th>D67N</th>
<th>S68G</th>
<th>K70R</th>
<th>L74V</th>
<th>K103N</th>
<th>Y115F</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TDF 1-3</strong></td>
<td></td>
<td>No mutations detected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TDF 4</strong></td>
<td></td>
<td>56.18%</td>
<td>1.46%</td>
<td>98.31%</td>
<td>2.03%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TDF 5</strong></td>
<td>0.76%</td>
<td>95.54%</td>
<td>18.54%</td>
<td>0.42%</td>
<td></td>
<td></td>
<td></td>
<td>6.16%</td>
<td></td>
</tr>
<tr>
<td><strong>TDF 6</strong></td>
<td></td>
<td>98.05%</td>
<td>3.22%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Representative Response Profiles for Subjects on TDF-Containing Regimens
Subject TDF-1
ATV/FTC/TDF

Plasma HIV-1 RNA Log 10 c/mL

Clone Results Below Noise Threshold

ZDV/3TC/NFV (W85-89)

Clone Results Below Noise Threshold

ATV/FTC/TDF (W439-448)

RTV/TDF/ATV/FTC (W405-424)

RTV/ATV/FTC/TDF (W448-479)

Study Week
Subject TDF-4
3TC/NVP/TDF

Clonal Seq
K65R: 56.18%
D67G: 1.46%
S68G: 98.31%
L74V: 2.03%
K65R, S68G: 55.94%

Clonal Seq
K65R: 23.47%
D67N: 0.72%
D67G: 0.86%
S68G: 91.09%
L74V: 1.21%
K65R, S68G: 22.98%

Plasma HIV-1 RNA Log10 c/mL

Study Week

Clonal Seq=RT aa 56-120
Subject TDF-5
3TC/TDF/EFV

Clonal Seq
A62V: 0.76%
K65R: 95.54%
D67G: 18.54%
S68G: 0.42%
Y115F: 6.16%

Clonal Seq
K65R: 98.15%
D67G: 96.25%
S68G: 0.4%
Y115F: 89.63%

Clonal Seq=RT aa 56-120
# Clonal Analysis for Subjects Receiving an ABC-Based Regimen

<table>
<thead>
<tr>
<th>Subj. ID</th>
<th>A62V</th>
<th>K65R</th>
<th>D67G</th>
<th>D67N</th>
<th>S68G</th>
<th>K70R</th>
<th>L74V</th>
<th>K103N</th>
<th>Y115F</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABC1-4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>No mutations detected</td>
<td></td>
</tr>
<tr>
<td>ABC 5</td>
<td></td>
<td></td>
<td>0.45%</td>
<td>0.43%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABC 6</td>
<td>0.87%</td>
<td>0.81%</td>
<td>2.87%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABC 7</td>
<td>1.73%</td>
<td>1.59%</td>
<td>6.57%</td>
<td>6.34%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABC 8</td>
<td>1.4%</td>
<td></td>
<td>97.91%</td>
<td>99.0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABC 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>98.57%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Representative Response Profiles for Subjects on ABC-Containing Regimens
Subject ABC-4
ABC/3TC/EFZ

Plasma HIV-1 RNA Log10 c/mL

Study Week

Clone Results Below Noise Threshold

Pop Seq WT
ABC FC=0.8
3TC FC=0.8
EFV FC=1.3

Pop Seq WT

Pop Seq WT

Pop Seq
K103N,
M184V,
P225H/P

Pop Seq WT

ABC FC=0.8
3TC FC=0.8
EFV FC=1.3

Clone Results Below Noise Threshold
Subject ABC-6
RTV/ATV/ABC/3TC

Clonal Seq=RT aa 56-120

Plasma HIV-1 RNA Log10 c/mL

Study Week

ABC/ZDV/3TC (W-148-52)
3TC/RTV/ABC/ATV (W53-55)
RTV/ATV/ABC/3TC (W55-121)

Clonal Seq
K65R: 0.87%
D67N: 2.87%
D67G: 0.81%
Representative Response Profile for a Subject not on ABC- or TFV-Containing Regimens
Subject 17
ZDV/3TC/EFZ

Plasma HIV-1 RNA Log10 c/mL

Study Week

Pop Seq, K103N

Clonal Seq K103N: 84.52%

Pop Seq M184V, K103N

Pop Seq WT
ZDV FC=0.5
3TC FC=0.7
EFV FC=0.7

Clonal Seq=RT aa 56-120
Limitation

- No information available about adherence
Conclusions

- Most viremic subjects (6/9 on ABC, 3/6 on TFV, 1 on ZDV/3TC) had no minority (or majority) variants detected in RT amino acids 56 to 120.
  - Ultra-deep sequencing may not add to management of all

- In some TFV-treated subjects, minority variants with NRTI mutations at 62V, 67G/N, 68G or 74V were detected.
  - One TFV-treated subject with no known prior ABC had a majority 65R with a minority 74V detected at two timepoints.

- In some ABC-treated subjects, minority variants with NRTI mutations at 65R, 67G/N or 70R were detected.

- No K70E detected.
## Acknowledgements

<table>
<thead>
<tr>
<th>GlaxoSmithKline, RTP, NC</th>
<th>Vanderbilt, Nashville, TN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>R. Lanier</strong></td>
<td><strong>P. Rebeiro</strong></td>
</tr>
<tr>
<td><strong>454 Life Technologies</strong></td>
<td><strong>S. Stinnette</strong></td>
</tr>
<tr>
<td><strong>L. Du</strong></td>
<td><strong>S. Bebawy</strong></td>
</tr>
<tr>
<td></td>
<td><strong>T. Sterling</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Comprehensive Care Ctr, Nashville, TN</strong></td>
</tr>
<tr>
<td></td>
<td><strong>C. McGowan</strong></td>
</tr>
</tbody>
</table>
Additional Background Material
## Error Rate Calculation (Subject 17, ZDV/3TC/EFZ)

### Estimated error rates for 454 sequencing:

<table>
<thead>
<tr>
<th>Enzyme/Sequencer</th>
<th>Error Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reverse transcriptase enzyme</td>
<td>1.00E-03</td>
</tr>
<tr>
<td>DNA polymerase</td>
<td>3.40E-05</td>
</tr>
<tr>
<td>FLX sequencer</td>
<td>2.00E-03</td>
</tr>
<tr>
<td>Estimate of overall error rate</td>
<td>3.03E-03</td>
</tr>
</tbody>
</table>

### Assuming this error rate, calculate the probability of observing n or more variants in N reads:

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of reads (N)</td>
<td>34036</td>
</tr>
<tr>
<td>% variants (with K65R)</td>
<td>0.270%</td>
</tr>
<tr>
<td>Number of variants (n)</td>
<td>91.8972</td>
</tr>
<tr>
<td>Expected number of variants due to errors</td>
<td>9.41E+01</td>
</tr>
<tr>
<td>Probability*</td>
<td>0.8961</td>
</tr>
</tbody>
</table>

* If this probability is small (e.g., less than 0.001) then there are many more variants than we would expect to find due to sequencing and PCR errors. Hence conclude it is an authentic variant. Otherwise, reject.